Who Should Be Monitored for Tardive Dyskinesia While Taking Reglan?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health to Specific Pharmaceutical Risks

If you or a loved one is taking Reglan (metoclopramide), you may wonder about the risk of tardive dyskinesia, a movement disorder that can become permanent. Medical guidelines emphasize that certain patients—especially those on long-term therapy or with specific health conditions—require careful monitoring. This page explains who needs monitoring and what that involves, building on decades of clinical experience with dopamine-blocking medications.

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) carries a boxed warning stating that it can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD involves potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Risk Factors and Incidence of Tardive Dyskinesia

Regarding the risk of TD from metoclopramide, data from a PubMed, Google Scholar, and Cross Reference search indicate that the risk is low, in the range of 0.1% per 1000 patient years (https://pubmed.ncbi.nlm.nih.gov/31050085/). This is far below a previously estimated 1%-10% risk suggested in treatment guidelines by regulatory authorities (https://pubmed.ncbi.nlm.nih.gov/31050085/). High-risk groups include elderly females, diabetics, patients with liver or kidney failure, and patients with concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). The risk of TD due to metoclopramide is far below approximated numbers in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). The approved indications for Reglan tablets include treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy, and relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan has not been shown to be safe and effective for gastroesophageal reflux treatment beyond 12 weeks, and it is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration with metoclopramide products should not exceed 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Prognosis and Long-Term Outcome

The prognosis for patients who develop TD after Reglan use is variable. The boxed warning describes TD as potentially irreversible, meaning that in some patients, the movement disorder may persist even after discontinuation of the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the natural history of TD can include partial or complete remission in some cases, particularly if the condition is recognized early and the offending agent is withdrawn promptly. The timeline between exposure to Reglan and documented harm is influenced by duration of treatment and cumulative dosage, with risk increasing over time (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The boxed warning emphasizes using Reglan for the shortest duration and periodically reassessing the need for continued treatment to minimize risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Adequacy of warnings regarding Reglan and TD is addressed by the boxed warning, which is the strongest warning required by the FDA. The warning clearly states that metoclopramide can cause TD, that the risk increases with duration and dosage, and that Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information also includes warnings and precautions about TD, other extrapyramidal symptoms, and neuroleptic malignant syndrome, advising avoidance of concomitant use of other drugs known to cause these conditions and avoidance in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms occur, immediate discontinuation and medical attention are recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For affected patients, prognosis-related considerations include the potential for irreversibility, the need for early detection, and the importance of discontinuing Reglan at the first sign of TD. The boxed warning advises immediate discontinuation in patients who develop signs or symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of TD is lower than previously estimated, but high-risk groups should be monitored closely (https://pubmed.ncbi.nlm.nih.gov/31050085/). The timeline between exposure and documented harm can vary, but the risk is cumulative, so longer exposure increases the likelihood of developing TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Overall, the long-term outcome of TD after Reglan use depends on factors such as the duration of exposure, the presence of risk factors, and the timeliness of intervention.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for tardive dyskinesia caused by Reglan?

The prognosis is variable. Tardive dyskinesia (TD) can be potentially irreversible, but some patients experience partial or complete remission, especially if Reglan is discontinued early. The outcome depends on factors like duration of exposure, cumulative dosage, and individual risk factors such as age and diabetes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

How common is tardive dyskinesia from Reglan?

The risk is low, estimated at 0.1% per 1000 patient years, which is lower than earlier estimates of 1-10% (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, high-risk groups such as elderly females, diabetics, and those on antipsychotics should be monitored closely.

What should I do if I develop symptoms of tardive dyskinesia while taking Reglan?

Immediately discontinue Reglan and seek medical attention. The boxed warning advises stopping the drug at the first sign of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Early detection and withdrawal improve the chance of recovery.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.